Trump signs order to speed up psychedelic research and access

President Donald Trump has signed an executive order that directs federal health and research agencies to speed up the development and approval of psychedelic-assisted therapies. The order, announced Monday morning, targets substances like psilocybin, MDMA, and ketamine, aiming to make them more accessible for treating conditions such as PTSD, depression, and addiction. It instructs the FDA, NIH, and VA to prioritize clinical trials, reduce regulatory hurdles, and expand funding for studies over the next three years.

The decision caught many by surprise, given Trump's traditionally tough-on-drugs stance. But it aligns with a quiet shift in recent years as both parties have warmed to the idea of using psychedelics in controlled medical settings. The administration argues the move could address the nation's ongoing mental health crisis, especially among veterans. Early data from pilot programs have shown promising results, and the VA is expected to launch new treatment trials by the end of the year.

Wall Street reacted quickly. Shares of companies like MindMed, Compass Pathways, and Atai Life Sciences surged between 15% and 30% in morning trading. Bloomberg noted the gains were some of the sharpest in the biotech sector this year. Investors see the order as a signal that the federal government is serious about integrating these therapies into mainstream medicine, potentially opening a multibillion-dollar market.

Still, the order has raised concerns. Some public health experts warn that moving too fast could risk patient safety, especially without long-term studies. Others point out that the directive doesn't change the legal status of these drugs outside of approved treatments, meaning recreational use remains illegal. There's also skepticism about whether agencies have the resources to handle the increased workload without delays elsewhere.

The move sidesteps Congress entirely, relying on executive authority to reshape drug policy. That's drawn criticism from lawmakers on both sides who say such a significant shift should require legislative debate. But supporters argue that bureaucracy has stalled progress for too long, and that this is a necessary step to get help to people who need it now.

This isn't the first time psychedelics have gained political attention. Several states, including Colorado and Oregon, have already legalized or decriminalized certain substances for therapeutic use. The federal government has granted 'breakthrough therapy' status to some psychedelic treatments, but full approval has been slow. Trump's order could accelerate that timeline dramatically.

For patients and advocates, the announcement feels like a turning point. After decades of stigma, psychedelics are being treated more like medicine and less like taboo. Whether this approach delivers real benefits-or creates new risks-will likely take years to sort out. But for now, the momentum is clearly shifting.